Live Breaking News & Updates on Supertrans Medical

Stay updated with breaking news from Supertrans medical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SuperTrans Medical appoints Australian partners to provide crucial clinical research in the battle against drug-resistant bacteria


Mar 15 2021
MELBOURNE, Australia, March 15, 2021 /PRNewswire/ SuperTrans Medical has announced the appointment of three Australian companies to play pivotal roles in an upcoming clinical drug trial that offers new hope in the plight against antimicrobial resistance (AMR), which the World Health Organisation (WHO) describes as a ‘silent pandemic’ and one of the biggest threats to global health.
International biopharmaceutical company SuperTrans Medical has announced the appointment of CMAX, Avance Clinical and Agilex Biolabs as its key clinical research partners to conduct the roll-out of Phase 1 human clinical trials in Australia during 2021 for its revolutionary new antibiotic.   
The drug uses SuperTrans Medical’s patented Intelligent Repurposing™ technology, originally invented at Stanford University. This approach involves the chemical attachment of a permeator unit to an existing mainstay antibiotic, which leads to its ‘revitalisation’ by enabling ....

South Australia , Yvonne Lungershausen , Stephen Patterson , Sepehr Shakib , Lewis Neville , Agilex Biolabs , Jason Valentine , Supertrans Medical Limited , Industries Sector Plan , Clinical Research , Stanford University , World Health Organisation , Supertrans Medical , Avance Clinical , Intelligent Repurposing , Antimicrobial Agents , Urinary Tract Infections , Australian Minister , Investment Stephen Patterson , Medical Industries Sector Plan , Marshall Liberal Government , Growth State Plan , Medical Industries , Royal Adelaide Hospital , Professor Sepehr Shakib , Trans Medical ,

'Supercharger' to revive mainstay antibiotic in global fight against antibiotic resistance


Feb 11 2021
Revolutionary new treatment that involves the revitalisation of a well-known antibiotic to enter clinical trials in Australia this year
MELBOURNE, Australia, Feb. 11, 2021 /PRNewswire/ SuperTrans Medical (STM), a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant bacteria, has published First-In-Class, successful pre-clinical results and announced plans to begin clinical trials in Australia later this year for its lead candidate STM-001.
Offering new hope in the plight against antimicrobial resistance (AMR), STM has applied its patented permeator technology to the widely used antibiotic vancomycin through a process of intelligent repurposing .  The technology, originally developed at Stanford University, attaches easily to the existing antibiotic. The modified antibiotic can effectively penetrate into urgent threat bacterial pathogens allowing a highly effective eradication of superbugs.   ....

Lewis Neville , Supertrans Medical Limited , Permeator Technology , Stanford University , Supertrans Medical , Urinary Tract Infections , Antimicrobial Agents , Trans Medical , Guanidinium Rich Molecular Transporter , Trans Medical Limited , லெவிஸ் நெவில் , ஸ்டான்போர்ட் பல்கலைக்கழகம் , சிறுநீர் பாதை நோய்த்தொற்றுகள் , டிரான்ஸ் மருத்துவ , டிரான்ஸ் மருத்துவ வரையறுக்கப்பட்டவை ,